Target
CDK9
1 product, 2 indications
Indications
Newly diagnosed glioblastoma or anaplastic astrocytoma (1 products)
glioblastoma (1 products)
Loading...
1 drug
8 abstracts
Abstract
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.Org: Cyclacel Ltd,
Abstract
Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.Org: Durarte, Cedars-Sinai Cancer Institute, City of Hope Orange County Lennar Foundation Center, Virginia Cancer Specialists (VCS) Research Institute, Community Regional Cancer Care - East,
Abstract
Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.Org: Cyclacel Pharmaceuticals Inc,
Abstract
In silico design of novel multitarget small molecule inhibitors to treat PTEN-mutant endometrial carcinoma.Org: Molecular Targeted Therapeutics Laboratory,
Abstract
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).Org: MGH Cancer Center, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Medical College of Wisconsin, Norris Comprehensive Cancer Center,
Abstract
Development of BLX-3030, a potent and selective inhibitor of CDK9 for the treatment of NMYC-driven NEPCS.Org: Biolexis Therapeutics, Inc.,
Abstract
Olutasidenib in post-venetoclax patients with mIDH1 AML.Org: Georgia Cancer Center, Augusta University, Medical College of Georgia at Augusta University, Augusta, GA, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA,
Abstract
Novel multitarget small molecule inhibitor LCI133 and synthetic lethality in endometrial carcinoma via CDK9/PI3K axis.Org: Division of Gynecologic Oncology, University of Pennsylvania, Levine Cancer Institute, Atrium Health Carolinas Medical Center, Molecular Targeted Therapeutics Laboratory, Department of Cancer Biostatistics,
Drug
Zotiraciclib